Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Fibrinolytic Agents in Complicated Pleural Effusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03716375
Recruitment Status : Not yet recruiting
First Posted : October 23, 2018
Last Update Posted : November 6, 2018
Sponsor:
Information provided by (Responsible Party):
Baoping XU, Beijing Children's Hospital

Brief Summary:
Intrapleural administration of fibrinolytic therapy, urokinase in parapneumonic effusion and empyema has been shown to decrease the need for surgical intervention and length of hospital stay. Pleural adhesions are easily formed in the early stages of empyema and the thickening of the pleural causes subsequent treatment difficulties. The goal of this study was to observe and compare the efficacy of treatment in empyema patients with urokinase and chest drainage or with chest drainage or with chest tube drainage alone so as to provide evidence for guiding clinical treatment.

Condition or disease Intervention/treatment Phase
Complicated Pleural Effusion/ Empyema Drug: Intrapleural Medications Not Applicable

Detailed Description:

Empyema, a collection of pus in the pleural space has been continuously associated with morbidity and mortality rates of 10-20%. Increase in the incidence of empyema with change in pattern of disease and the causative organism has demonstrated a challenge in the diagnosis and treatment. In the recent years many studies and clinical trials have been done among adults and children regarding the optimal empyema treatment and its efficacy and some are still in the process of further study. Appropriate treatment according to the three stages of empyema (i.e. exudative stage, fibropurulent stage and organizing stage) has constantly been under frequent research, finding which treatment is more effective (i.e. antibiotics, chest tube drainage, intrapleural fibrinolytics, VATS and decortication alone in combination) and when is the proper time for intervention. Intrapleural instillation of urokinase was initially described in 1994 on pediatric population and since then lots of studies have been reported. Therefore, the investigators conducted a randomized controlled study with relevant inclusion and exclusion criteria to assess the success rate of intrapleural urokinase administration among the patients with Complicated Pleural Effusion (CPE) / empyema comparing it with drainage alone. All case patients in this study received antibiotic empirically or with sensitivity when microbiological tests available, chest tube drainage along with urokinase intrapleural therapy or drainage alone for treatment of CPE/empyema.

Patients will be randomized into two groups: one is chest tube drainage and intrapleural fibrinolytic agent and another is chest tube drainage alone. The group with intrapleural fibrinolytic agent will receive urokinase 10ml of 1000 IU/ml in children aged less than or equal to 1 year or 40ml of 1000 IU/ml in children aged more than 1 year and the other group with drainage alone. The first instillation of the agent is done at the time of chest tube insertion of 12Fr or 14Fr tube, after instillation the chest tube is closed for 4 hours. The chest tube is then unclamped after 4 hours and connected to the suction system with pressure of -20cm H2O for 8 hours and the process is repeated every 12 hourly. The procedure was done for 3 consecutive days and was evaluated with daily chest X-ray and followed chest tube removal when the drainage was less than 40ml/day or according to the clinical and radiological response of patients with treatment.

The trial is being done for 12 months with 80 participants taken from one center, Beijing children´s Hospital.

The aim of this study is to evaluate difference among intrapleural urokinase as the initial treatment for children with pleural empyema against chest tube drainage alone. Length of hospital stay, number of days chest tube drainage, number of days of fever after tube insertion, complications such bleeding, chest pain will be compared between the two groups.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study of Fibrinolytic Treatment for Purulent Pleural Effusion in Children
Estimated Study Start Date : November 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : April 30, 2020

Arm Intervention/treatment
Experimental: use of fibrinolytic agent
Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
Drug: Intrapleural Medications
urokinase

No Intervention: no use of any drug
Chest tube drainage



Primary Outcome Measures :
  1. Length of hospital stay [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Days of fever after chest tube insertion [ Time Frame: 3 to 4 days ]
  2. Duration of drainage [ Time Frame: 2 weeks ]
  3. Complications [ Time Frame: 2weeks ]
    number of participants changed to open thoracotomy

  4. Failure rate [ Time Frame: 2weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Pleural Empyema diagnostic criteria were based on the "Zhu Futang Practical Pediatrics" (the 7th Edition) and The American Thoracic Society consensus guidelines for management of empyema.

  • Frank pus at tapping or organism demonstrated on Gram stain or culture
  • Pleural fluid pH < 7.2, glucose < 60mg/dl, LDH>1000 IU/ml, protein > 3g/ml and white cells 15,000 cells/mm cube
  • Physical, radiological and laboratory signs accompanying the relevant clinical picture

Inclusion Criteria:

  • Previously healthy child with age between 1 month to 18 years
  • Admitted with diagnosis of Pleural empyema requiring chest tube insertion and fibrinolytics (as judged by the attending physician) with the following criteria:

I. Pneumonia with pleural empyema based on chest ultrasound and CT scan. II. Need for further intervention based on clinical criteria (persistent fever despite antibiotics for at least 48 hours, significant respiratory distress, tachypnea or hypoxia as a result of pleural empyema.

Exclusion Criteria:

Subject will be excluded if she or he has one of the followings:

  • Empyema as result of tuberculosis, fungus or noninfectious causes (e.g. malignancy)
  • Known coagulation impairment
  • Suspected allergy to urokinase
  • Child has already undergone drainage procedure or drug was used in 30 days (e.g.

chest tube or VATS

  • Chronic lung diseases or other chronic illnesses (e.g. Immunodeficiency, neurological impairment possible)
  • Significant thoracic trauma in last 2 months
  • Severe arterial hypertension
  • Presence of Pneumothorax before treatment (i.e. bronchopleural fistula)
  • Pregnancy
  • Breast feeding
  • Poor compliance
  • Contraindication in the presence of fibrinolytic agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03716375


Contacts
Layout table for location contacts
Contact: Xu Baoping, MD, PhD +861059616308 xubaopingbch@163.com

Sponsors and Collaborators
Beijing Children's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Xu Baoping, MD, PhD Beijings Children´s Hospital of Capital Medical University, China

Publications of Results:
Layout table for additonal information
Responsible Party: Baoping XU, Chief of Respiratory Department, Beijing Children's Hospital
ClinicalTrials.gov Identifier: NCT03716375     History of Changes
Other Study ID Numbers: BCHlung011
First Posted: October 23, 2018    Key Record Dates
Last Update Posted: November 6, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Baoping XU, Beijing Children's Hospital:
Pleural empyema, urokinase

Additional relevant MeSH terms:
Layout table for MeSH terms
Pleural Effusion
Empyema
Pleural Diseases
Respiratory Tract Diseases
Suppuration
Infection
Inflammation
Pathologic Processes
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action